{"entity":{"id":"nct07106762","kind":"trial","name":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy","aka":["IZABRIGHT-Bladder01"],"tldr":"A phase 2/3 trial of Cisplatin, Gemcitabine and Carboplatin in bladder & urothelial cancer, run by Bristol-Myers Squibb, now recruiting.","summary":"Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy is a phase 2/3 interventional study registered as NCT07106762 by Bristol-Myers Squibb, with 470 participants planned, started 2025-09-30 and due to reach its primary completion in 2029-01-26. Interventions recorded: Iza-bren, Cisplatin, Gemcitabine and Carboplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07106762","url":"https://clinicaltrials.gov/study/NCT07106762"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","muscle-invasive-bladder-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cisplatin","gemcitabine","carboplatin"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07106762","phase":"2/3","setting":"IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment","sponsor":"Bristol-Myers Squibb","participation":[{"nct":"NCT07106762","source":"https://clinicaltrials.gov/study/NCT07106762","fetchedAt":"2026-10-07T16:55:27.525Z","studySha256":"3402f93900d4170dcf309131aeebbf762546af4317007fd5ca65ae86bc10f30c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-07-29","leadSponsor":"Bristol-Myers Squibb","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":470,"enrolmentType":"ESTIMATED","siteCount":163,"recruitingSiteCount":122,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Czechia","France","Germany","Ireland","Israel","Italy","Japan","Netherlands","Norway","Romania","Spain","Sweden","Switzerland","United Kingdom","United States"]}],"started":"2025-09-30","startedType":"actual","enrolled":470,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07106762/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"muscle-invasive-bladder-cancer","kind":"cancer","name":"Muscle-invasive and advanced bladder cancer","route":"/cancers/muscle-invasive-bladder-cancer/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}